Skip to main content
Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
Made on Aug 7, 2026
Price at call $484.03
6-month call Bear -7.4%
Target by Feb 2027 $448.00
Great value below $300.00
Model v0.6.0

Projection vs Actual (6M history + forecast)

The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change -7.4% to $448.00
Predicted High $490.00 at 1 month
Predicted Low $448.00 at 6 months
Max Drawdown (predicted) -7.4%

Forecast

The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded. Predicted Aug 7, 2026 1:18 am
Bear VRTX trends lower to $448.00 (-7.4% from $484.03) by Feb 2027. ride-then-fade
ThesisSentiment tailwind and low-beta stability keep VRTX firm near-term, but heavy overvaluation versus fair value gradually pulls the price lower over the six-month window as pipeline enthusiasm cools.
Invalidated ifA sustained break above $510 on positive pipeline data, or a break below $440 on negative catalyst, would falsify this gradual mean-reversion path.
Checkpointtime after the call Datewhen it gets graded Predictedthe claim: closing price Current priceactual close — fills in over time Predicted returnpredicted vs $484.03 at call Conv.brain's confidence, 1–10 Driverwhy the brain put the point here
Prediction made Aug 7, 2026 $484.03 at call The anchor — every point below is measured from this price and date.
2 weeks Aug 21, 2026 $457.98–$510.08 typical range · internal point $487.50 ±5.4% 7/10 Sentiment tailwind and risk-on regime extend near-term drift higher
What actually happened: closed $540.26 on Aug 20, 2026 = +11.6% vs the call (predicted +0.7%)  ·  direction MISS (called flat, was up)  ·  off by 10.9 pp  ·  accuracy 4/10  ·  typical range ±5.4%: OUTSIDE the band  ·  S&P -1.5% over the same window — beat it
1 month Sep 7, 2026 $446.28–$521.78 typical range · internal point $490.00 ±7.8% 6/10 Pipeline anticipation and analyst reaffirmations sustain modest bid
2 months Oct 7, 2026 $482.00 -0.4% 5/10 Momentum cools; valuation gravity begins to weigh
3 months Nov 7, 2026 $473.00 -2.3% 5/10 Fair-value gap pressures multiple; low beta cushions decline
4 months Dec 7, 2026 $465.00 -3.9% 4/10 Year-end positioning trims richly-valued large-cap biotech
5 months Jan 7, 2027 $455.00 -6.0% 4/10 Value convergence continues absent fresh catalyst
6 months Feb 7, 2027 $448.00 -7.4% 3/10 Drift toward deterministic baseline as sentiment fades

Why ranges on the short rungs? A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here — three prompt formulations all lost to simply predicting zero — while the stock's own volatility scale (σ×√t) described those windows well. So the short rungs claim what's actually knowable: the typical travel, with earnings timing flagged where the variance will come from. The internal point calls keep being generated and graded to map where real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.

Deterministic control (v0.3 value line) targets $436.26 (-9.9%) — both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it. Brain: claude-opus-4-7.

Weaknesses

0 blocking · 1 degraded · 0 notes — follow the chain top-down (cause → effect).
  • Degraded
    [warning] Valuation is extremely fragile — almost no scenarios support the current price
    upstream:valuation-synthesis

Equation Inputs

Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.

Value anchors (from deep analysis)

Price at call$484.03
Composite fair value$205.77
Signal-adjusted fair value$202.29
DCF fair value$185.62
Anchored-PE fair value$335.79
Buy-below (value lens)$300.00
Value net score-76
Value confidence6 / 10
Quality net score+50
Memo confidence7 / 10
Deserved value (base)
Quality tilt
Deserved value (used)
Coherence (value × quality)

Price behaviour (trailing — shapes the realism line)

Realized volatility (annualized) 1m 19.3%  3m 27.0%  6m 30.1%  
Daily σ (realism noise)1.7%
Beta vs S&P 500 1m 0.12  3m 0.22  5m 0.43  
Trailing 6-month return2.9%

Knobs (equation params)

ladderArray
llm_modelclaude-opus-4-7
max_tokens3000
control_knobsArray
Neutral band (%)5
earnings_briefv1
prompt_versionp1
control_versionv0.3.0

Version & Tech Chain

What produced this prediction — stamped on the record so versions can be compared by success rate later.
Model v0.6.0 #271041f8fcd5

Tech composition (what this version is built from)

#ProcessKindGroup
1 Synthesis valuation-synthesis deterministic final
2 Scenario Analysis scenario-valuation deterministic valuation
3 Valuation / Mispricing ext-lens-value llm extended
4 Company Quality ext-lens-quality llm extended
5 Forensic Memo (combiner) ext-forensic-memo llm extended
6 Classification company-classification llm foundation
7 Live Quote fmp-quote data market-data

Inputs used (the runs that fed this prediction)

Upstream processRanLagRun id
company-classification Aug 7, 2026 freshest VRTX-20260807-002946-bd56
ext-forensic-memo Aug 7, 2026 freshest ext-VRTX-20260807-010334-e2e5
ext-lens-quality Aug 7, 2026 freshest ext-VRTX-20260807-010334-e2e5
ext-lens-sentiment Aug 7, 2026 freshest ext-VRTX-20260807-010334-e2e5
ext-lens-value Aug 7, 2026 freshest ext-VRTX-20260807-010334-e2e5
scenario-valuation Aug 7, 2026 freshest VRTX-20260807-002946-bd56
valuation-synthesis Aug 7, 2026 freshest VRTX-20260807-002946-bd56

Inputs flagged 7d+ behind the freshest one may be stale relative to the rest of the analysis.

Saved History

1 frozen snapshot — the record we score once predictions mature.
MadeModelCallAt callTargetExp.Eval due
Aug 7, 2026 v0.6.0 Bear $484.03 $448.00 -7.4% Feb 2027 viewing

Not Yet Modeled

What this v0.6.0 forecast deliberately ignores — the work ahead, in plain sight.
  • Scenario probabilities — one path, no bull/bear split (base_prob = 1.0).
  • Intraday / sub-2-week behaviour — the first claim is at 14 days by design (EOD product).
  • Position sizing / portfolio context — the path is a price claim only.